Discontinuing antidepressant treatment in major depression.
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Maintenance treatments in bipolar disorders and schizophrenia are securely established, and their discontinuation is associated with high but modifiable risk of early relapse. The benefits of long-term antidepressant treatment in major depression and the risks of discontinuing medication at various times after clinical recovery from acute depression are not as well defined. Computerized searching found 27 studies with data on depression risk over time including a total of 3037 depressive patients treated for 5.78 (0-48) months and then followed for 16.6 (5-66) months with antidepressants continued or discontinued. Compared with patients whose antidepressants were discontinued, those with continued treatment showed much lower relapse rates (1.85 vs. 6.24%/month), longer time to 50% relapse (48.0 vs. 14.2 months), and lower 12-month relapse risk (19.5 vs. 44.8%) (all p < 0.001). However, longer prior treatment did not yield lower postdiscontinuation relapse risk, and differences in relapses off versus on antidepressants fell markedly with longer follow-up. Contrary to prediction, gradual discontinuation (dose-tapering or use of long-acting agents) did not yield lower relapse rates. Relapse risk was not associated with diagnostic criteria. More previous illness (particularly three or more prior episodes or a chronic course) was strongly associated with higher relapse risk after discontinuation of antidepressants but had no effect on response to continued treatment; patients with infrequent prior illness showed only minor relapse differences between drug and placebo treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While Viguera et al. (1998) found that patients with more prior episodes benefited more from antidepressant treatment”
From Predicting relapse after antidepressant withdrawal – a systematic review (2017) · cites this paper as Viguera et al. 1998
In the citing paper
“In addition, discontinuation itself is likely to have an effect on relapse, indicated by the increased risk in the early months following discontinuation, which is independent of length of prior treatment (Viguera et al. 1998).”
From Predicting relapse after antidepressant withdrawal – a systematic review (2017) · cites this paper as Viguera et al. 1998
In the citing paper
“Several meta-analyses (Viguera et al. 1998; Geddes et al. 2003; Kaymaz et al. 2008; Glue et al. 2010; Andrews et al. 2011) have, however, examined it, with none finding a significant effect.”
From Predicting relapse after antidepressant withdrawal – a systematic review (2017) · cites this paper as Viguera et al. 1998
Citations
Cites
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370
Lifetime Prevalence of Specific Psychiatric Disorders in Three Sites
Robins, L. N. (1984) · Archives of General Psychiatry · doi:10.1001/archpsyc.1984.01790210031005 · Cited by 2,550 · cited 1×
“(2) Slow removal of an antidepressant, or stopping a long-acting agent (such as fluoxetine or a standard monoamine oxidase inhibitor [MAOI]), would be followed by less morbid risk in the ensuing months than would abrupt or rapid discontinuation of long-term treatment with a short-acting antidepressant.”
Cross-national epidemiology of major depression and bipolar disorder
Weissman, M. M. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540040037030 · Cited by 2,302
Three-Year Outcomes for Maintenance Therapies in Recurrent Depression
Frank, E. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810240013002 · Cited by 1,297
(1994) · PharmacoResources · doi:10.1007/bf03289581 · Cited by 974
Hirschfeld, R. M. A. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540280071036 · Cited by 895
Prien, R. F. (1984) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790220086014 · Cited by 565
Treatment of Depression by Drugs and Psychotherapy
KLERMAN, G. L., DIMASCIO, A., WEISSMAN, M., PRUSOFF, B., & PAYKEL, E. S. (1974) · American Journal of Psychiatry · doi:10.1176/ajp.131.2.186 · Cited by 500
Risk of Recurrence Following Discontinuation of Lithium Treatment in Bipolar Disorder
Suppes, T. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810360046007 · Cited by 392 · cited 2×
“1 (6-60) months yielded a computed time to 50% risk of relapse (-+ SE) of 48.”
Long-term Outcome of Episodes of Major Depression: Clinical and Public Health Significance
Keller, M. B. (1984) · JAMA · doi:10.1001/jama.252.6.788 · Cited by 295
Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment
Viguera, A. C. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830130055011 · Cited by 246
Sertraline in the Prevention of Depression
Doogan, D. P., & Caillard, V. (1992) · British Journal of Psychiatry · doi:10.1192/bjp.160.2.217 · Cited by 245
Outcome After Rapid vs Gradual Discontinuation of Lithium Treatment in Bipolar Disorders
Faedda, G. L. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820180046005 · Cited by 239 · cited 2×
“1 (6-60) months yielded a computed time to 50% risk of relapse (-+ SE) of 48.”
The Prophylactic Efficacy of Fluoxetine in Unipolar Depression
Montgomery, S. A., Dufour, H., Brion, S., Gailledreau, J., Laqueille, X., Ferrey, G., Moron, P., Parant-Lucena, N., Singer, L., Danion, J. M., et al. (1988) · British Journal of Psychiatry · doi:10.1192/s0007125000297328 · Cited by 232
(1992) · American Journal of Psychiatry · doi:10.1176/ajp.149.6.795 · Cited by 228 · cited 2×
“1 (6-60) months yielded a computed time to 50% risk of relapse (-+ SE) of 48.”
Low Levels and Lack of Predictors of Somatotherapy and Psychotherapy Received by Depressed Patients
Keller, M. B. (1986) · Archives of General Psychiatry · doi:10.1001/archpsyc.1986.01800050064007 · Cited by 228
An evaluation of continuation therapy with tricyclic antidepressants in depressive illness
Mindham, R. H. S., Howland, C., & Shepherd, M. (1973) · Psychological Medicine · doi:10.1017/s0033291700046304 · Cited by 225
Kane, J. M. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290090053011 · Cited by 212 · cited 2×
“1 (6-60) months yielded a computed time to 50% risk of relapse (-+ SE) of 48.”
Neuroleptic Withdrawal in Schizophrenic Patients
Baldessarini, R. J. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950150021002 · Cited by 195
Self-citationParoxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression
Montgomery, S. A., & Dunbar, G. (1993) · International Clinical Psychopharmacology · doi:10.1097/00004850-199300830-00009 · Cited by 188
Depression: a neglected major illness.
Greenberg, P. E., Stiglin, L. E., Finkelstein, S. N., & Berndt, E. R. (1993) · PubMed · Cited by 181
(1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810090025004 · Cited by 157
Old Age Depression Interest Group, Jacoby, R., Lunn, A. D., Ardern, M., Bergmann, K., Conway, J., Cooling, N., Davies, G., Fisk, J., Gehlhaar, E., et al. (1993) · British Journal of Psychiatry · doi:10.1192/bjp.162.2.175 · Cited by 155
Glen, A. I. M., Johnson, A. L., & Shepherd, M. (1984) · Psychological Medicine · doi:10.1017/s0033291700003068 · Cited by 141
McCombs, J. S., Nichol, M. B., Stimmel, G. L., Sclar, D. A., Beasley, C. M., & Gross, L. S. (1990) · PubMed · Cited by 135
Kind, P., & Sorensen, J. (1993) · International Clinical Psychopharmacology · doi:10.1097/00004850-199300730-00010 · Cited by 134
Maintenance Therapy for Chronic Depression: A Controlled Clinical Trial of Desipramine
Kocsis, J. H. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830090013002 · Cited by 121
Continuation Therapy with Amitriptyline in Depression
Coppen, A., Ghose, K., Montgomery, S., Rama Rao, V. A., Bailey, J., & Jorgensen, A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.1.28 · Cited by 103
Depression vulnerability and 5-hydroxytryptophan prophylaxis
van Praag, H. M., & de Haan, S. (1980) · Psychiatry Research · doi:10.1016/0165-1781(80)90049-9 · Cited by 101
Effects of the Rate of Discontinuing Lithium Maintenance Treatment in Bipolar Disorders
Baldessarini, R. J., Tondo, L., Faedda, G. L., Suppes, T. R., Floris, G., & Rudas, N. (1996) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v57n1001 · Cited by 93
Self-citation(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.551 · Cited by 82
Discontinuation of Maintenance Treatment in Bipolar Disorder: Risks and Implications
Suppes, T., Baldessarini, R. J., Faedda, G. L., Tondo, L., & Tohen, M. (1993) · Harvard Review of Psychiatry · doi:10.3109/10673229309017072 · Cited by 80
Self-citationRobinson, D. S., Sc, L., Bennett, B., Laux, D. E., Devereaux, E., Kayser, A., CORCELLA, J., & ALBRIGHT, D. (1991) · PubMed · Cited by 79
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.1.31 · Cited by 75
Phenelzine for chronic depression: a study of continuation treatment.
Harrison, W. M., Rabkin, J. G., Stewart, J. W., McGrath, P. J., TRICAMO, E., & Quitkin, F. M. (1986) · PubMed · Cited by 72
Maintenance therapy with amitriptyline: a controlled trial
Stein, M. K., Rickels, K., & Weise, C. (1980) · American Journal of Psychiatry · doi:10.1176/ajp.137.3.370 · Cited by 65
Recurrence of depression after discontinuation of long-term amitriptyline treatment
(1982) · American Journal of Psychiatry · doi:10.1176/ajp.139.3.325 · Cited by 62
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.548 · Cited by 61
Prophylactic efficacy of maprotiline on unipolar depression relapse.
Rouillon, F., Serrurier, D., Miller, H. D., & Gerard, M. J. (1991) · PubMed · Cited by 52
Treatment and outcome in secondary depression: a naturalistic study of 1087 patients.
Black, D. W., Winokur, G., & Nasrallah, A. T. (1987) · PubMed · Cited by 44
Björk, K. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb11122.x · Cited by 38
Kupfer, D. J. (1992) · British Journal of Psychiatry · doi:10.1192/bjp.161.3.309 · Cited by 37
Unipolar depression in the elderly
Cook, B. L., Helms, P. M., Smith, R. E., & Tsai, M. (1986) · Journal of Affective Disorders · doi:10.1016/0165-0327(86)90031-5 · Cited by 36
Use of Phenelzine in Continuation Therapy
Davidson, J., & Raft, D. (1984) · Neuropsychobiology · doi:10.1159/000118076 · Cited by 33
Baldessarini, R. J., Suppes, T., & Tondo, L. (1996) · American Journal of Therapeutics · doi:10.1097/00045391-199607000-00004 · Cited by 27
Self-citationIs There a Long-Term Protective Effect of Mood-Altering Agents in Unipolar Depressive Disorder?
Baldessarini, R. J., & Tohen, M. F. (1988) · Springer eBooks · doi:10.1007/978-3-642-73280-5_12 · Cited by 11
Self-citationProphylactic effect of mianserin on recurrent depression
Kishimoto, A., Mizukawa, R., Matsuzaki, F., Hazama, H., Kamase, H., Tanaka, K., & Kunimoto, N. (1994) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1994.tb01484.x · Cited by 11
Cited by
Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12599-8 · Cited by 945
Malhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842
“…continuation of antidepressant treatment at the therapeutic dose that was effective during acute treatment for at least 1 year following an initial episode and at least 3 years for recurrent episodes (Bauer, 2007) and episodes which included psychotic features (Viguera et al., 1998) (CBR).”
BackgroundViguera, A. C., Nonacs, R., Cohen, L. S., Tondo, L., Murray, A., & Baldessarini, R. J. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.2.179 · Cited by 488
Self-citationBauer, M., Bschor, T., Pfennig, A., Whybrow, P. C., Angst, J., Versiani, M., Möller, H.-J., WFSBP Task Force on Unipolar Depres, Bauer, M., Bschor, T., et al. (2007) · The World Journal of Biological Psychiatry · doi:10.1080/15622970701227829 · Cited by 477
Davies, J., & Read, J. (2019) · Addictive Behaviors · doi:10.1016/j.addbeh.2018.08.027 · Cited by 387
“In addition to the obvious economic costs incurred, the human costs of long-term use are well documented, being linked with serious adverse effects such as increased severe side-effects, (Ferguson, 2001) the impairment of patients' autonomy and resilience (increasing their dependence on medical help) (Kendrick, 2015),…”
Background
Metadata
- Authors
- Viguera, A. C., Baldessarini, R. J., & Friedberg, J.
- Affiliations
- Harvard University (US)
- Corresponding author
- Baldessarini, Ross J.
- Venue
- Harvard Review of Psychiatry
- Published
- 1998-03
- Volume
- 5
- Issue
- 6
- Pages
- 293-306
- ISSN
- 1067-3229 (ISSN-L)
- OpenAlex
- W2061813324
- Cited by
- 145
- References
- 47
- Citations by year
- 2026: 2 · 2024: 9 · 2023: 2 · 2022: 3 · 2021: 4 · 2020: 7 · 2019: 5 · 2018: 4 · 2017: 3 · 2016: 3 · 2015: 5 · 2014: 5 · 2013: 5 · 2012: 9
- FWCI
- 3.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Harvard Review of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5k05mh047370-25)
- National Institute of Mental Health (MH47370)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- antidepressant discontinuation, major depressive disorder, relapse risk, maintenance therapy, long-term antidepressant treatment, dose tapering, chronic depression, time to relapse
- MeSH terms
- Analysis of Variance, Antidepressive Agents, Depressive Disorder, Humans, Survival Analysis, Statistics, Nonparametric, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.